These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 26957200)

  • 41. Opportunities to exploit non-neutralizing HIV-specific antibody activity.
    Ackerman ME; Alter G
    Curr HIV Res; 2013 Jul; 11(5):365-77. PubMed ID: 24191934
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention.
    Vargas-Inchaustegui DA; Robert-Guroff M
    Curr HIV Res; 2013 Jul; 11(5):407-20. PubMed ID: 24191937
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.
    Gauduin MC; Parren PW; Weir R; Barbas CF; Burton DR; Koup RA
    Nat Med; 1997 Dec; 3(12):1389-93. PubMed ID: 9396610
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of Fc-mediated antibody function in protective immunity against HIV-1.
    Lewis GK
    Immunology; 2014 May; 142(1):46-57. PubMed ID: 24843871
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New-Generation High-Potency and Designer Antibodies: Role in HIV-1 Treatment.
    Gama L; Koup RA
    Annu Rev Med; 2018 Jan; 69():409-419. PubMed ID: 29029583
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges.
    Bomsel M; Tudor D; Drillet AS; Alfsen A; Ganor Y; Roger MG; Mouz N; Amacker M; Chalifour A; Diomede L; Devillier G; Cong Z; Wei Q; Gao H; Qin C; Yang GB; Zurbriggen R; Lopalco L; Fleury S
    Immunity; 2011 Feb; 34(2):269-80. PubMed ID: 21315623
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reconstitution and characterization of antibody repertoires of HIV-1-infected "elite neutralizers".
    Sun Z; Li J; Hu X; Shao Y; Zhang MY
    Antiviral Res; 2015 Jun; 118():1-9. PubMed ID: 25770672
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Contribution of NK Cell Education to both Direct and Anti-HIV-1 Antibody-Dependent NK Cell Functions.
    Kristensen AB; Kent SJ; Parsons MS
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514913
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies.
    von Bredow B; Arias JF; Heyer LN; Moldt B; Le K; Robinson JE; Zolla-Pazner S; Burton DR; Evans DT
    J Virol; 2016 Jul; 90(13):6127-6139. PubMed ID: 27122574
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mucosal immunization with inactivated HIV-1-capturing nanospheres induces a significant HIV-1-specific vaginal antibody response in mice.
    Akagi T; Kawamura M; Ueno M; Hiraishi K; Adachi M; Serizawa T; Akashi M; Baba M
    J Med Virol; 2003 Feb; 69(2):163-72. PubMed ID: 12683403
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Towards HIV-1 remission: potential roles for broadly neutralizing antibodies.
    Halper-Stromberg A; Nussenzweig MC
    J Clin Invest; 2016 Feb; 126(2):415-23. PubMed ID: 26752643
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Model for competition from self during passive immunization, with application to broadly neutralizing antibodies for HIV.
    Ali Tabei SM; Li Y; Weigert M; Dinner AR
    Vaccine; 2012 Jan; 30(3):607-13. PubMed ID: 22119591
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Involvement of the complement system in antibody-mediated post-exposure protection against human immunodeficiency virus type 1.
    Gauduin MC; Weir R; Fung MS; Koup RA
    AIDS Res Hum Retroviruses; 1998 Feb; 14(3):205-11. PubMed ID: 9491910
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antibody-mediated immune exclusion of HIV.
    Ruprecht RM; Lakhashe SK
    Curr Opin HIV AIDS; 2017 May; 12(3):222-228. PubMed ID: 28422786
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-retroviral antibody FcγR-mediated effector functions.
    Bournazos S; Ravetch JV
    Immunol Rev; 2017 Jan; 275(1):285-295. PubMed ID: 28133801
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Simultaneous approach using systemic, mucosal and transcutaneous routes of immunization for development of protective HIV-1 vaccines.
    Belyakov IM; Ahlers JD
    Curr Med Chem; 2011; 18(26):3953-62. PubMed ID: 21824096
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HIV/AIDS: allied responses.
    Mascola JR
    Nature; 2007 Sep; 449(7158):29-30. PubMed ID: 17805280
    [No Abstract]   [Full Text] [Related]  

  • 58. Vector-Mediated In Vivo Antibody Expression.
    Schnepp BC; Johnson PR
    Microbiol Spectr; 2014 Aug; 2(4):AID-0016-2014. PubMed ID: 26104192
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Multifaceted Nature of Immunoglobulin A and Its Complex Role in HIV.
    Lopez E; Shattock RJ; Kent SJ; Chung AW
    AIDS Res Hum Retroviruses; 2018 Sep; 34(9):727-738. PubMed ID: 30056749
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adeno-associated virus delivery of broadly neutralizing antibodies.
    Schnepp BC; Johnson PR
    Curr Opin HIV AIDS; 2014 May; 9(3):250-6. PubMed ID: 24638019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.